Lifeloc Q2 2026 revenue up 10% to $2.445M, net loss narrows to $(134K)

Lifeloc Technologies, Inc

2026-Q2 EPS reported -$0.10 revenue$4,738,769

Q2 2026 net revenue $2.445M, up 10% YoY; net loss $(134K) or $(0.05) diluted vs $(394K) or $(0.14) in Q2 2025.
Six-month revenue $4.739M, loss $(287K) or $(0.10) vs $4.496M and $(686K) or $(0.25) prior year.
Gross margin improved to 45% from 42% YoY; R&D spend $560K on SpinDetect analyzer development.
SpinDetect oral-fluid analyzer beta testing to start; limited commercial launch targeted for Q1 2027.
Closed $500K loan from Chairman/CFO at 10.5% interest, secured by all assets, to fund operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.